Citations

Clear

10 citation(s) found for "Stockholm, Daniel".

TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
Gessain, Grégoire , Anzali, Ahmed-Amine , Lerousseau, Marvin , Mulder, Kevin , Bied, Mathilde , Aupérin, Anne , Stockholm, Daniel , Signolle, Nicolas , Sassi, Farah , Costa, Maria Eugénia Marques Da , Sayadi, Alexandre , Weidner, Daniela , Blampey, Quentin , Nakkireddy, Sumanth Reddy , Dutertre, Charles‐Antoine , Walter, Thomas , Marhic, Alix , Guerlain, Joanne , Casiraghi, Odile , Marques Da Costa, Maria Eugenia , Marchais, Antonin , Sayadi, Alexandre , Weidner, Daniela , Uderhardt, Stefan , Blampey, Quentin , Nakkireddy, Sumanth Reddy , Broutin, Sophie , Dutertre, Charles-Antoine , Busson, Pierre , Walter, Thomas , Marhic, Alix , Moya-Plana, Antoine , Guerlain, Johanne , Breuskin, Ingrid , Casiraghi, Odile , Gorphe, Philippe , Classe, Marion , Scoazec, Jean-Yves , Blériot, Camille , Ginhoux, Florent , Auperin, Anne , Uderhardt, Stefan , Moya‐Plana, Antoine

Mayo Clinic

Cancer Discovery | September 13, 2024 | Volume: 14 | Issue: 12 | Pages: 2352-2366

10.1158/2159-8290.cd-24-0018 | PMID 39270324 Get It

Abstract Patients with head and neck squamous cell carcinomas (HNSCC) often have poor outcomes due to suboptimal risk management and treatment strategies; yet integrating novel prognostic biomarkers into clinical practice is challenging. Here, we report the presence of multinucleated giant cells (MGC)—a type of macrophages—in tumors from patients with HNSCC, which are associated with a favorable prognosis in treatment-naive and preoperative chemotherapy–treated patients. Importantly, MGC density increased in tumors following preoperative therapy, suggesting a role of these cells in the antitumoral response. To enable clinical translation of MGC density as a prognostic marker, we developed a deep-learning model to automate its quantification on routinely stained pathological whole slide images. Finally, we used spatial transcriptomic and proteomic approaches to describe the MGC-related tumor microenvironment and observed an increase in central memory CD4 T cells. We defined an MGC-specific signature resembling to TREM2-expressing mononuclear tumor-associated macrophages, which colocalized in keratin tumor niches. Significance: Novel individual biomarkers are needed to guide therapeutic decisions for patients with head and neck cancer. We report for the first time, granulomas of TREM2-expressing multinucleated giant macrophages in keratin-rich tumor niches, as a biomarker of favorable prognosis and developed a deep-learning model to automate its quantification on routinely stained pathological slides.
Biomarkers of Alzheimer’s Disease and Cerebrovascular Disease in Relation to Depressive Symptomatology in Individuals With Subjective Cognitive Decline
Zapater‐Fajarí, Mariola , Diaz‐Galvan, Patricia , Cedrés, Nira , Sterner, Therese Rydberg , Sacuiu, Simona , Zettergren, Anna , Zetterberg, Henrik , Blennow, Kaj , Kern, Silke , Hidalgo, Vanesa , Westman, Eric , Ferreira, Daniel , Zetterberg, Henrik , Westman, Eric , Ferreira, Daniel , Diaz-Galvan, Patricia , Rydén, Lina , Wærn, Margda , Salvador, Alicia , Skoog, Ingmar

Mayo Clinic

The Journals of Gerontology: Series A | September 14, 2023 | Volume: 79 | Issue: 2 | Pages: No page available

10.1093/gerona/glad216 | PMID 37708068 Get It

Abstract Background Subjective cognitive decline (SCD) has gained recent interest as a potential harbinger of neurodegenerative diseases such as Alzheimer’s disease (AD) and cerebrovascular disease (CVD). In addition, SCD can be related to depressive symptomatology. However, the association between AD and CVD biomarkers, depressive symptomatology, and SCD is still unclear. We investigated the association of AD and CVD biomarkers and depressive symptomatology with SCD in individuals with subjective memory complaints (SCD-memory group) and individuals with subjective concentration complaints (SCD-concentration group). Methods We recruited a population-based cohort of 217 individuals (all aged 70 years, 53% female participants, 119 SCD-memory individuals, 23 SCD-concentration individuals, and 89 controls). AD and CVD were assessed through cerebrospinal fluid levels of the Aβ42/40 ratio and phosphorylated tau, and white matter signal abnormalities on magnetic resonance imaging, respectively. Associations between biomarkers, depressive symptomatology, and SCD were tested via logistic regression and correlation analyses. Results We found a significant association between depressive symptomatology with SCD-memory and SCD-concentration. Depressive symptomatology was not associated with AD and CVD biomarkers. Both the phosphorylated tau biomarker and depressive symptomatology predicted SCD-memory, and the Aβ42/40 ratio and depressive symptomatology predicted SCD-concentration. Conclusions The role of depressive symptomatology in SCD may differ depending on the stage within the spectrum of preclinical AD (as determined by amyloid-beta and tau positivity), and does not seem to reflect AD pathology. Our findings contribute to the emerging field of subclinical depressive symptomatology in SCD and clarify the association of different types of subjective complaints with distinct syndromic and biomarker profiles.
Pyruvate dehydrogenase kinase regulates vascular inflammation in atherosclerosis and increases cardiovascular risk
Forteza, María J. , Berg, M , Edsfeldt, Andreas , Sun, Jiangming , Kareinen, Ilona , Casagrande, Felipe Beccaria , Zhang, Song , Vučković, Ivan , Dzeja, Petras P. , Trauelsen, Mette , Schwartz, Thue W. , Dib, Lea , Herrmann, Joerg , Monaco, Claudia , Matic, Ljubica , Gonçalves, Isabel , Ketelhuth, Daniel F.J. , Kareinen, Ilona , Hedin, Ulf , Gisterå, Anton , Dib, Lea , Monaco, Claudia , Ketelhuth, Daniel F J , Vuckovic, Ivan , Baumgartner, Roland , Polyzos, Konstantinos A.

Mayo Clinic

Cardiovascular Research | March 3, 2023 | Volume: 119 | Issue: 7 | Pages: 1524-1536

10.1093/cvr/cvad038 | PMID 36866436 Get It

Abstract Aims Recent studies have revealed a close connection between cellular metabolism and the chronic inflammatory process of atherosclerosis. While the link between systemic metabolism and atherosclerosis is well established, the implications of altered metabolism in the artery wall are less understood. Pyruvate dehydrogenase kinase (PDK)-dependent inhibition of pyruvate dehydrogenase (PDH) has been identified as a major metabolic step regulating inflammation. Whether the PDK/PDH axis plays a role in vascular inflammation and atherosclerotic cardiovascular disease remains unclear. Methods and results Gene profiling of human atherosclerotic plaques revealed a strong correlation between PDK1 and PDK4 transcript levels and the expression of pro-inflammatory and destabilizing genes. Remarkably, the PDK1 and PDK4 expression correlated with a more vulnerable plaque phenotype, and PDK1 expression was found to predict future major adverse cardiovascular events. Using the small-molecule PDK inhibitor dichloroacetate (DCA) that restores arterial PDH activity, we demonstrated that the PDK/PDH axis is a major immunometabolic pathway, regulating immune cell polarization, plaque development, and fibrous cap formation in Apoe−/− mice. Surprisingly, we discovered that DCA regulates succinate release and mitigates its GPR91-dependent signals promoting NLRP3 inflammasome activation and IL-1β secretion by macrophages in the plaque. Conclusions We have demonstrated for the first time that the PDK/PDH axis is associated with vascular inflammation in humans and particularly that the PDK1 isozyme is associated with more severe disease and could predict secondary cardiovascular events. Moreover, we demonstrate that targeting the PDK/PDH axis with DCA skews the immune system, inhibits vascular inflammation and atherogenesis, and promotes plaque stability features in Apoe−/− mice. These results point toward a promising treatment to combat atherosclerosis.
Sex differences in brain atrophy in dementia with Lewy bodies
Oltra, Javier , Schwarz, Christopher G. , Nedelská, Zuzana , Przybelski, Scott A. , Inguanzo, Anna , Diaz‐Galvan, Patricia , Lowe, Val J. , Oppedal, Ketil , Blanc‬, ‪Frederic, Kramberger, Milica G. , Taylor, John‐Paul , Snædal, Jón , Walker, Zuzana , Westman, Eric , Habich, Annegret , Schwarz, Christopher G , Nedelska, Zuzana , Inguanzo, Anna , Diaz-Galvan, Patricia , Oppedal, Ketil , Lemstra, Afina W , Hort, Jakub , Padovani, Alessandro , Rektorova, Irena , Bonanni, Laura , Massa, Federico , Taylor, John Paul , Snædal, Jon , Walker, Zuzana , Antonini, Angelo , Segura, Barbara , Junque, Carme , Westman, Eric , Boeve, Brad , Aarsland, Dag , Kantarci, Kejal , Ferreira, Daniel , Habich, Annegret , Lemstra, Afina W. , Hort, Jakub , Padovani, Alessandro , Rektorová, Irena , Massa, Federico , Antonini, Angelo , Segura, Bàrbara , Junqué, Carme , Boeve, Bradley F. , Aarsland, Dag , Kantarci, Kejal , Ferreira, Daniel

Mayo Clinic

No container title available | January 27, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2516427/v1 | PMID 36747755 Get It

Abstract Background and objectives. Sex is an important contributing factor to neuroimaging phenotypes in brain disorders. However, little is known about the contribution of sex differences to the neurodegeneration in dementia with Lewy bodies (DLB). We investigated sex differences in probable DLB patients by using both visual rating scales of lobar atrophy and automated estimations of regional atrophy. Methods. We included 442 probable DLB patients from the European-DLB consortium and the Mayo Clinic who have magnetic resonance imaging (MRI) data available. We assessed sex differences and the sex-by-age interaction in two largely independent samples through visual rating scales of lobar atrophy (n = 333; mean age 73 ± 8 years, 62% males) and automated regional estimations of gray matter (GM) volume and mean cortical thickness (CTh) (n = 165; mean age 69 ± 9 years, 72% males). We used binary logistic regression and ANOVA for statistical analysis. Results. We found a statistically significantly higher likelihood of frontal atrophy measured by the global cortical atrophy-frontal subscale (GCA-F) in males (40% of males had an abnormal GCA-F score versus 29% of females, P-value = 0.006). Using automated estimations, we found smaller GM volumes in 6 cortical regions in males compared with females, as well as smaller GM volume in the entorhinal cortex and thinner olfactory cortices in females, compared with males. The sex-by-age interaction showed statistically significant results in 6 cortical volumes and 7 mean CTh estimations (P-value ≤ 0.05), accentuated in the right middle frontal gyrus (FDR-adjusted P-value = 0.047). These cross-sectional interactions indicated that while females have statistically significantly less atrophy than males at younger ages, differences become non-significant at older ages, with females showing the same level of atrophy than males around the age of 75. Conclusions. This study demonstrates sex differences on brain atrophy in probable DLB. While male DLB patients have a more widespread pattern of cortical atrophy at younger ages, these sex differences tend to disappear with increasing age. Longitudinal studies will help establish these cross-sectional findings and inform on sex and age considerations to the use of MRI in clinical routine, as the field moves towards precision medicine.
The protective gene dose effect of the APOEε2 allele on gray matter volume in cognitively unimpaired individuals
Salvadó, Gemma , Ferreira, Daniel , Operto, Grégory , Cumplido‐Mayoral, Irene , Falcón, Carles , Vilor‐Tejedor, Natàlia , Minguillón, Carolina , Groot, Colin , Barkhof, Frederik , Scheltens, Philip , Ossenkoppele, Rik , Kern, Silke , Zettergren, Anna , Hort, Jakub , Stomrud, Erik , Westen, Danielle van , Hansson, Oskar , Westman, Eric , Gispert, Juan Domingo , ADNI, ALFA study†, BioFINDER,, Crous‐Bou, Marta , Arenaza-Urquijo, Eider M , Cacciaglia, Raffaele , Falcon, Carles , Vilor-Tejedor, Natàlia , Minguillon, Carolina , Groot, Colin , van der Flier, Wiesje M , Barkhof, Frederik , Scheltens, Philip , Ossenkoppele, Rik , Skoog, Ingmar , Stomrud, Erik , van Westen, Danielle , Hansson, Oskar , Molinuevo, José Luis , Wahlund, Lars-Olof , Westman, Eric , Gispert, Juan Domingo , Ferreira, Daniel , Hort, Jakub , Arenaza‐Urquijo, Eider M. , Flier, Wiesje M. van der , Skoog, Ingmar , Molinuevo, José Luís , Wahlund, Lars‐Olof , ADNI, ALFA study†, BioFINDER,

Mayo Clinic

Alzheimer's & Dementia | December 8, 2021 | Volume: 18 | Issue: 7 | Pages: 1383-1395

10.1002/alz.12487 | PMID 34877786 Get It

AbstractIntroductionHarboring two copies of the apolipoprotein E (APOE) ε2 allele strongly protects against Alzheimer's disease (AD). However, the effect of this genotype on gray matter (GM) volume in cognitively unimpaired individuals has not yet been described.MethodsMulticenter brain magnetic resonance images (MRIs) from cognitively unimpaired ε2 homozygotes were matched (1:1) against all other APOE genotypes for relevant confounders (n = 223). GM volumes of ε2 genotypic groups were compared to each other and to the reference group (APOE ε3/ε3).ResultsCarrying at least one ε2 allele was associated with larger GM volumes in brain areas typically affected by AD and also in areas associated with cognitive resilience. APOE ε2 homozygotes, but not APOE ε2 heterozygotes, showed larger GM volumes in areas related to successful aging.DiscussionIn addition to the known resistance against amyloid‐β deposition, the larger GM volumes in key brain regions may confer APOE ε2 homozygotes additional protection against AD‐related cognitive decline.
Fully bayesian longitudinal unsupervised learning for the assessment and visualization of AD heterogeneity and progression
Poulakis, Konstantinos , Ferreira, Daniel , Pereira, Joana B. , Vemuri, Prashanthi , Westman, Eric , Vemuri, Prashanthi , Westman, Eric , Ferreira, Daniel , Smedby, Örjan

Mayo Clinic

Aging | July 9, 2020 | Volume: 12 | Issue: 13 | Pages: 12622-12647

10.18632/aging.103623 | PMID 32644944 Get It